TG Therapeutics, Inc.
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $8.15B |
| Revenue | $700M |
| Net Income | $462M |
| Total Assets | $1.53B |
| Net Assets | $583M |
| Employees | 399 |
| Value | |
| P/E | 17.64x |
| P/B | 13.97x |
| PEG | 0.06x |
| P/S | 11.63x |
| EV/EBITDA | 53.92x |
| FCF Yield | -0.17% |
| Profitability | |
| ROE | 79.21% |
| ROA | 30.21% |
| Op. Margin | 21.35% |
| Revenue Growth | 69.56% |
| Earnings Growth | 290.85% |
| Financial Health | |
| Debt Ratio | 162.18% |
| Total Debt | $754M |
| FCF | $-14M |
| Cash | $442M |
| Current Ratio | 5.81x |
| Net Debt/EBITDA | 1.98x |
| Performance | |
| 1Y Return | 51.32% |
| 1M Return | 34.97% |
| From 52W High | -1.57% |
| 1Y MDD | -42.01% |
| Trading | |
| Volume | 5,426,735 shares |
| Trading Value | $288M |
| Per Share | |
| EPS | $3.13 |
| BPS | $4.53 |
Company Info
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.